S
Sam Schulman
Researcher at McMaster University
Publications - 501
Citations - 40585
Sam Schulman is an academic researcher from McMaster University. The author has contributed to research in topics: Warfarin & Dabigatran. The author has an hindex of 74, co-authored 460 publications receiving 35175 citations. Previous affiliations of Sam Schulman include Sahlgrenska University Hospital & Karolinska University Hospital.
Papers
More filters
Journal ArticleDOI
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients.
Sam Schulman,U. Angerås,David Bergqvist,Bengt I. Eriksson,Michael R. Lassen,William D. Fisher +5 more
TL;DR: A definition of major bleeding that should be applicable to all agents that interfere with hemostasis is developed and is to seek approval from the regulatory authorities to enhance its incorporation into future clinical trial protocols.
Journal ArticleDOI
Prevention of VTE in Nonsurgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Yngve Falck-Ytter,Charles W. Francis,Norman A. Johanson,Catherine Curley,Ola E. Dahl,Sam Schulman,Thomas L. Ortel,Stephen G. Pauker,Clifford W. Colwell +8 more
TL;DR: In this article, the authors focus on optimal prophylaxis to reduce postoperative pulmonary embolism and DVT following major orthopedic surgery, and suggest the use of low-molecular-weight heparin in preference to the other agents we have recommended as alternatives.
Journal ArticleDOI
Dabigatran versus warfarin in the treatment of acute venous thromboembolism
Sam Schulman,Clive Kearon,Ajay K. Kakkar,Patrick Mismetti,Sebastian Schellong,Henry Eriksson,David Baanstra,Janet Schnee,Samuel Z. Goldhaber,S. Schul +9 more
TL;DR: For the treatment of acute venous thromboembolism, a fixed dose of dabigatran is as effective as warfarin, has a safety profile that is similar to that of warfar in, and does not require laboratory monitoring.
Journal ArticleDOI
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up
Behnood Bikdeli,Mahesh V. Madhavan,David Jiménez,Taylor Chuich,Isaac Dreyfus,Elissa Driggin,Caroline Der Nigoghossian,Walter Ageno,Mohammad Madjid,Yutao Guo,Liang V. Tang,Yu Hu,Jay Giri,Mary Cushman,Isabelle Quéré,Evangelos Dimakakos,C. Michael Gibson,C. Michael Gibson,Giuseppe Lippi,Emmanuel J. Favaloro,Jawed Fareed,Joseph A. Caprini,Alfonso Tafur,John R. Burton,Dominic P. Francese,Elizabeth Y. Wang,Anna Falanga,Claire McLintock,Beverley J. Hunt,Alex C. Spyropoulos,Geoffrey D. Barnes,John W. Eikelboom,John W. Eikelboom,Ido Weinberg,Sam Schulman,Marc Carrier,Gregory Piazza,Gregory Piazza,Joshua A. Beckman,P. Gabriel Steg,Gregg W. Stone,Stephan Rosenkranz,Samuel Z. Goldhaber,Samuel Z. Goldhaber,Sahil A. Parikh,Manuel Monreal,Harlan M. Krumholz,Stavros Konstantinides,Jeffrey I. Weitz,Gregory Y.H. Lip,Gregory Y.H. Lip +50 more
TL;DR: The current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexistingThrombotic disease who develop CO VID-19 are reviewed.
Journal ArticleDOI
Prevention of VTE in Orthopedic Surgery Patients
Yngve Falck-Ytter,Charles W. Francis,Norman A. Johanson,Catherine Curley,Ola E. Dahl,Sam Schulman,Thomas L. Ortel,Stephen G. Pauker,Clifford W. Colwell +8 more
TL;DR: Optimal strategies for thromboprophylaxis after major orthopedic surgery include pharmacologic and mechanical approaches.